Tirzepatide for PCOS: What the Evidence Actually Shows

If you have polycystic ovary syndrome and you have watched friends lose 40 pounds on Zepbound, you have probably wondered whether the same drug would fix the thing that PCOS actually does to you — the missing periods, the stubborn weight, the acne, the hair, the years of being told to “just lose weight” by people who never explained how.

Here is the honest answer as of September 2026: tirzepatide is not a PCOS treatment, and it has never been tested as one in a trial big enough to settle the question. But it is not a blank page either. One randomized trial, one very large real-world cohort and one properly designed trial now enrolling give us more than we had a year ago.

This article walks through exactly what exists, what it shows, and what it does not show.

Is tirzepatide approved for PCOS?

No — not in the United States, and not anywhere else.

Tirzepatide is the active ingredient in two different American brands, and it matters which one you are talking about:

• Mounjaro is approved to improve blood sugar control in adults and in children 10 and older with type 2 diabetes, and carries an additional indication to reduce cardiovascular risk in adults with type 2 diabetes [13].
• Zepbound is approved to reduce excess body weight and maintain that reduction long term in adults with obesity, or with overweight plus at least one weight-related condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity [12].

Neither label mentions PCOS. If a clinician prescribes tirzepatide to someone with PCOS, it is either under one of those approved indications — many women with PCOS also meet the weight criteria — or it is fully off-label. Off-label prescribing is legal and common, but it means the FDA has not reviewed the drug for that use.

A quick disambiguation for US readers: in the United Kingdom and some other countries, “Mounjaro” is the brand name used for weight management as well as diabetes. In the US the two uses are split across two brand names. If you read a British article about Mounjaro and PCOS, it is talking about the same molecule in a differently branded box.

What does the one randomized trial actually show?

The only published randomized controlled trial of tirzepatide in PCOS was reported in Diabetes, Obesity and Metabolism in June 2026 [1][2]. It is small, and knowing its design tells you how much weight to put on it.

Sixty Chinese women with PCOS and overweight or obesity were randomly assigned to one of two groups for 16 weeks:

• Metformin alone — 1,000 mg twice a day
• Metformin plus low-dose tirzepatide — the same metformin, plus tirzepatide started at 2.5 mg once weekly for four weeks and then held at 5 mg once weekly

Both groups got metformin. So the trial answers a specific question: what does adding tirzepatide do on top of metformin? It does not answer whether tirzepatide beats metformin.

Weight and body composition. The combination group lost an average of 10.4 kg (about 23 pounds). The metformin-only group lost 1.7 kg (under 4 pounds). Visceral fat — the fat around the organs that drives insulin resistance — fell far more in the combination group [1].

Periods. Every participant had irregular cycles at the start. After 16 weeks, cycles returned to a regular pattern in 53.6 percent of the combination group (15 of 28) versus 21.4 percent of the metformin group (6 of 28), a statistically significant difference [2].

Hormones — and this is the nuanced part. Total testosterone and DHEA-S fell significantly more in the combination group. But there was no significant difference between the groups in SHBG, estradiol, prolactin, LH, the LH/FSH ratio, or the free androgen index [2]. The free androgen index is the number many clinicians actually watch for hyperandrogenism, because it accounts for how much testosterone is biologically available. Anti-Müllerian hormone, a marker tied to the ovarian follicle pool, fell more in the combination group (down 3.64 ng/mL versus 1.00 ng/mL).

So the picture is not “tirzepatide fixes PCOS hormones.” It is closer to “tirzepatide produced a lot of weight loss, and some hormone measures moved with it while others did not.”

Pregnancy. After week 16 everyone was switched to metformin alone, barrier contraception was required for a further eight weeks, and pregnancy outcomes were assessed between weeks 25 and 48. In that window, 57.1 percent of the combination group had a pregnancy (16 of 28) versus 25.0 percent of the metformin group (7 of 28), driven mainly by natural conception (39.3 percent, 11 of 28, versus 14.3 percent, 4 of 28) [2].

That last number gets shared on social media a lot. Read the design before you read the headline: 28 women per arm, one country, 16 weeks of treatment, an open-label trial where everyone knew what they were taking, and every participant had overweight or obesity to begin with. Nobody was still taking tirzepatide when these pregnancies occurred.

Why might tirzepatide help PCOS at all?

PCOS is not one disease with one cause, but insulin resistance sits near the center of it for a large share of people who have it. High insulin levels push the ovaries to make more androgens and lower SHBG, the protein that keeps testosterone bound and inactive. More free androgens disrupt the signal that triggers ovulation. Cycles stretch out or stop.

Losing a meaningful amount of weight improves insulin sensitivity, which can loosen that whole knot. That is why weight loss has been first-line advice in PCOS care for decades — and why the advice has been so frustrating, because PCOS itself makes weight loss harder.

Tirzepatide activates two gut hormone receptors, GIP and GLP-1, and produces more weight loss on average than any other approved weight-management drug in head-to-head testing. If weight loss is the lever, a stronger lever should in principle do more.

The word “in principle” is doing real work there. Nobody has demonstrated that tirzepatide does anything to PCOS that is independent of the weight loss, and the hormone findings above are exactly what you would expect from weight loss alone.

Do women with PCOS lose weight as well as anyone else on tirzepatide?

This one now has a decent answer.

A retrospective study published in the Journal of the Endocrine Society in August 2026 looked at 54,114 women prescribed tirzepatide through a digital weight-management service in the UK between February 2024 and January 2025. Of those, 4,241 (7.84 percent) reported having PCOS [3].

At 10 months, women with PCOS had lost an average of 19.40 percent of their starting body weight. Women without PCOS had lost 18.74 percent. The difference was not statistically significant. Among the women with PCOS, 57.66 percent had lost at least 20 percent of their body weight by 10 months [3].

The practical takeaway: PCOS does not appear to blunt how well tirzepatide works for weight. That is genuinely useful information, because many women with PCOS have been told their body “won’t respond” to weight-loss treatment.

Two caveats. The number of women with PCOS who actually reached the 10-month mark was small (40 of them), so the confidence interval around that 19.40 percent is wide. And PCOS status was self-reported, not confirmed by diagnostic criteria.

Are doctors already prescribing it for PCOS?

Widely, yes — though usually under a weight or diabetes rationale rather than a PCOS one.

A Polish study published in Diabetes, Obesity and Metabolism in 2026 followed 38,263 adult women with a coded PCOS diagnosis in one private healthcare network. Overall, 11.9 percent had a recorded prescription for a GLP-1 receptor agonist or tirzepatide, and 42.8 percent had metformin. Among the incretin users, 75.5 percent were also on metformin, and only 11.5 percent had coded type 2 diabetes — meaning most were not being treated for diabetes at all. Their median BMI was 31.2, compared with 26.3 for metformin-only users and 22.1 for untreated women [4].

Use rose sharply over time. The authors described it as expansion “beyond classical glycemic indications toward weight-focused and cardiometabolic management” [4]. This is Polish data, not American, but the prescribing pattern will look familiar to anyone in a US PCOS support group.

What do the guidelines say?

The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome is the document most endocrinologists and gynecologists work from. It contains 254 recommendations and practice points [6].

The systematic review commissioned to inform that guideline’s section on anti-obesity drugs found eleven trials covering 545 people in the intervention arms — and concluded that “published data examining the effects of anti-obesity agents in women with PCOS are very limited,” calling this a high priority for future research [7]. That review’s search ended in July 2022, before tirzepatide had any PCOS data at all.

So there is no guideline recommendation for tirzepatide in PCOS, and the absence reflects missing evidence rather than evidence of no effect.

What about semaglutide — is there more data there?

Slightly more, but not better. A scoping review published in Biomedicines in August 2026 pulled together 25 studies of semaglutide in PCOS. It reported weight loss averaging 7.6 to 11.5 kg over three to six months with improvements in fasting insulin and HOMA-IR, plus scattered reports of better menstrual regularity. The authors noted that most of the evidence came from observational work, small pilot studies, and conference abstracts rather than full papers [10].

A 2026 systematic review and meta-analysis in Clinical Obesity looked specifically at whether weight-lowering drugs improve natural fertility in women with overweight or obesity. It found only seven eligible trials totaling 575 women, six of which studied orlistat and exactly one of which studied semaglutide. None studied tirzepatide [8].

That is the state of the field. The drugs are being used by hundreds of thousands of women with PCOS, and the randomized evidence for reproductive outcomes fits in a single paragraph.

Is there a real PCOS trial running?

Yes, and it is the most important thing on this page.

PERIODS (ClinicalTrials.gov identifier NCT07326111) is a randomized, double-blind, placebo-controlled phase 4 trial run by the University of Bonn with four collaborating German centers [5].

• Who: 198 planned participants, women aged 18 to 45, at least three years past their first period and premenopausal, BMI of 27 or above, PCOS by Rotterdam criteria, with oligomenorrhea or secondary amenorrhea
• What: tirzepatide titrated over 20 weeks to the maximum tolerated dose, then held for 52 weeks — 72 weeks of treatment in total — against a matching placebo, with lifestyle advice in both arms
• Main measure: the menstrual bleeding ratio (periods divided by months) across the last 52 weeks
• Key secondary measure: the number of ovulations confirmed by weekly blood progesterone
• Also measured: AMH, total testosterone, SHBG, DHEA-S, androstenedione, the free androgen index, LH, FSH, estradiol, body weight and body composition
• Timing: enrollment opened December 9, 2025; primary results are expected around December 2028, with the study completing in 2029

Two design details are worth noticing. Because it is placebo-controlled and double-blind, it can separate a real drug effect from expectation. And because it measures confirmed ovulations rather than only self-reported bleeding, it tests the actual biology rather than a proxy for it.

Until PERIODS reports, anyone telling you tirzepatide is “proven” for PCOS is ahead of the evidence.

What should you know about birth control if you take tirzepatide?

This deserves its own section because it is tirzepatide-specific and it catches people out.

Tirzepatide slows how fast the stomach empties. In the pharmacokinetic study submitted with the marketing application, a single 5 mg dose taken alongside a combined oral contraceptive cut peak blood levels of ethinyl estradiol by 59 percent, norgestimate by 66 percent and norelgestromin by 55 percent, and delayed the time to peak by 2.5 to 4.5 hours. Total exposure across the day fell about 20 to 23 percent [9][12].

Because of this, both the Mounjaro and Zepbound labels instruct people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting the drug and for four weeks after every dose increase [12][13]. Non-oral methods — IUDs, implants, injections, the patch, the ring — are not affected.

Semaglutide, liraglutide, exenatide and dulaglutide do not carry this warning. Tirzepatide is the outlier.

A 2026 review in Maturitas pointed out a related open question: the same gastric-emptying effect could in theory alter oral progestogens used for endometrial protection or gynecologic disease control, which many women with PCOS take. No study has tested that, and the authors were careful to call the concern biologically plausible but unproven [9].

There is a second, separate reason contraception matters here. Weight loss can restore ovulation in someone who was not ovulating. Restored ovulation means pregnancy becomes possible again, sometimes unexpectedly. Both labels state that tirzepatide may cause fetal harm and should be discontinued when pregnancy is recognized [12][13].

Questions worth asking your healthcare provider

No article can tell you whether a medication is right for you, and this one is not trying to. These are the questions that tend to produce a useful conversation:

• Given my BMI, my blood sugar numbers and my other conditions, do I meet the criteria for an approved indication, or would this be off-label?
• What would we be treating first — weight, insulin resistance, cycles, or fertility? How will we know if it is working?
• I take metformin. Would we continue it, and what does the combination evidence look like?
• I use an oral contraceptive. What should I switch to, and for how long around each dose change?
• If I want to try to conceive in the next year or two, how does that change the plan and the timing?
• What happens to my weight and my cycles if I stop?
• What will this cost me, and is there any chance my plan covers it?

The bottom line

Tirzepatide is not approved for PCOS, no guideline recommends it for PCOS, and the entire randomized evidence base is one 60-person, 16-week, open-label trial in which everyone also took metformin.

What that trial and the surrounding real-world data suggest is narrower and more believable than the social media version: tirzepatide produces substantial weight loss in women with PCOS, at about the same rate as in women without it, and that weight loss is associated with more regular cycles and more pregnancies. Some androgen measures improve; the free androgen index and SHBG did not separate from metformin alone.

Whether tirzepatide does anything for PCOS beyond what the weight loss does is an open question that PERIODS was built to answer, and the answer is not due until late 2028.

If you are considering it, the most useful things you can bring to a clinician are the specific outcome you care most about, your contraception plan, and your timeline for pregnancy.

Sources

1. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial — Diabetes, Obesity and Metabolism, June 2026
2. Full text of the tirzepatide plus metformin PCOS trial — PubMed Central (PMC13341338)
3. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome — Journal of the Endocrine Society, August 2026
4. Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network — Diabetes, Obesity and Metabolism, 2026
5. A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS, NCT07326111) — ClinicalTrials.gov
6. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — Human Reproduction, 2023
7. Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline — Obesity Reviews, 2024
8. Weight-Lowering Drugs and Natural Female Fertility — A Systematic Review and Meta-Analysis — Clinical Obesity, 2026
9. Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction — Maturitas, September 2026
10. Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review — Biomedicines, August 2026
11. Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction — Medicina, July 2026
12. ZEPBOUND (tirzepatide) injection, US prescribing information, revised 08/2026 — US Food and Drug Administration
13. MOUNJARO (tirzepatide) injection, US prescribing information — Eli Lilly and Company